Article
Oncology
Wei Zhang, Seong-Min Lim, Juyoung Hwang, Srinivasan Ramalingam, Myunghee Kim, Jun-O Jin
Summary: MPLA enhances anti-cancer immunity mediated by anti-PD-L1 antibodies by activating pDCs and increasing IFN-α production.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Dahae Lee, Ji-Youn Kim, Hae-Won Kim, Jeong-Eun Yoo, Ki Sung Kang
Summary: The combination of genistein and atorvastatin significantly suppresses preadipocyte differentiation and downregulates adipogenic marker proteins, suggesting a potential alternative treatment for menopause-associated lipid metabolic disorders and obesity.
Article
Radiology, Nuclear Medicine & Medical Imaging
Kyung-Ho Jung, Jin Won Park, Jin Hee Lee, Seung Hwan Moon, Young Seok Cho, Kyung-Han Lee
Summary: A Zr-89-labeled anti-PD-L1 immune PET was developed for monitoring chemotherapy-mediated modulation of tumor PD-L1 expression. The method involved specific conjugation and radiolabeling of anti-PD-L1, showing efficient synthesis and specific targeting with favorable imaging properties. The PET imaging demonstrated the potential of this method in monitoring chemotherapy effects on tumor PD-L1 expression in living subjects.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Immunology
Hao Liu, Yanli Liu, Zhen Zhao, Yuanke Li, Bahaa Mustafa, Zhijin Chen, Ashutosh Barve, Akshay Jain, Xiaolan Yao, Guangfu Li, Kun Cheng
Summary: This study discovered anti-human PD-L1 single-domain antibodies (dAbs) that block the PD-1/PD-L1 interaction using a human domain antibody phage library for the first time. Among them, the CLV3 dAb showed the highest affinity and blocking efficacy to PD-L1, and significantly inhibited tumor growth in mice. These results suggest the potential of CLV3 dAb as an anti-PD-L1 inhibitor for cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yumei Li, Lingjun Wu, Yueying Liu, Siwen Ma, Biyi Huang, Xianjing Feng, Hui Wang
Summary: This study identified anti-PD-L1 single-domain antibodies from immunized llamas and constructed a novel multifunctional anti-PD-L1-CD16a-IL15 antibody. The fusion protein was able to recruit T cells and drive NK cells to specifically kill PD-L1-overexpressing tumor cells. In a xenograft model, it inhibited tumor growth with PBMCs, suggesting its potential for future cancer immunotherapy.
TRANSLATIONAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Dian Xiao, Longlong Luo, Jiaguo Li, Zhihong Wang, Lianqi Liu, Fei Xie, Jiannan Feng, Xinbo Zhou
Summary: The study confirmed for the first time that Atezolizumab is more suitable for designing ADCs compared to Avelumab, with the generated ADC 3 exhibiting potent tumor cell inhibitory activity and immune activation effects. These findings have positive implications for cancer therapy.
BIOORGANIC CHEMISTRY
(2021)
Article
Materials Science, Biomaterials
Tian Gao, Zheng Mao, Wenjing Li, Renjun Pei
Summary: Tumor immune evasion, mediated by the PD-L1/PD-1 axis, suppresses T cell function and enables cancer cells to escape immune surveillance. The aptamer PL1 specifically binds to PD-L1, inhibiting the PD-1/PD-L1 axis and restoring T cell proliferation and function. The similar efficacy and binding capacity of aptamer PL1 as an antibody suggest its potential as an alternative therapeutic agent for cancer immunotherapy.
JOURNAL OF MATERIALS CHEMISTRY B
(2021)
Article
Pharmacology & Pharmacy
Mark Stroh, Michelle Green, Bjorn L. Millard, Joshua F. Apgar, John M. Burke, Will Garner, Hong Lu, Susan K. Lyman, Luc R. Desnoyers, Jennifer Richardson, Alison Hannah, W. Michael Kavanaugh
Summary: CX-072 is an anti-PD-L1 Probody therapeutic designed to be preferentially activated by proteases in the tumor microenvironment. Model-guided drug development showed that the in vivo activity of CX-072 is consistent with theoretical predictions.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Biotechnology & Applied Microbiology
Iris M. Hagemans, Peter J. Wierstra, Kas Steuten, Janneke D. M. Molkenboer-Kuenen, Duco van Dalen, Martin ter Beest, Johan M. S. van der Schoot, Olga Ilina, Martin Gotthardt, Carl G. Figdor, Ferenc A. Scheeren, Sandra Heskamp, Martijn Verdoes
Summary: A set of molecularly defined multimodal antibody-based PD-L1 imaging agents were synthesized and validated for multiscale monitoring of PD-L1 expression and localization. PEGylation of the Fab fragment improved its half-life and tumor uptake. PD-L1 in tumors was clearly visualized by SPECT/CT and whole body fluorescence imaging. The imaging agent's intratumoral localization could be determined with cellular resolution using fluorescent microscopy.
JOURNAL OF NANOBIOTECHNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Zhifang Zhang, Annie Yang, Shyambabu Chaurasiya, Anthony K. Park, Jianming Lu, Sang-In Kim, Susanne G. Warner, Yate-Ching Yuan, Zheng Liu, Haiyong Han, Daniel Von Hoff, Yuman Fong, Yanghee Woo
Summary: The study demonstrates that genetically modified oncolytic viruses can significantly upregulate PD-L1 expression in PDAC, and virus-delivered anti-PD-L1 antibodies can enhance anti-tumor immune killing in PDAC.
CANCER GENE THERAPY
(2022)
Article
Biochemistry & Molecular Biology
Madhu S. Pandey, Chunlei Wang, Scott Umlauf, Shihua Lin
Summary: BsAbs or BsAbFPs are a promising strategy for cancer immunotherapy, with the challenge of assessing their potency when they engage two different signaling pathways simultaneously. A novel dual target reporter gene bioassay method has been developed, showing the potential mechanism of action and demonstrating the synergistic biological response of anti-PD-L1/CD40L BsAbFP compared to single treatments. This approach could be useful for developing bioassays for other BsAbs and combination therapy antibodies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Andrey Kulikov, Elena Shipaeva, Anastasia Dmitrieva, Vera Batrak, Georgy Shipunov, Colin Guy, Jill Smith, Ran Zhang, Michael Zhang, Jeff Duan, Anton Chestukhin, Sergei Barbashov, Mikhail Samsonov, Yan Lavrovsky
Summary: RPH-120 is a novel fully human anti-PD-L1 IgG1 monoclonal antibody with high affinity and promising bioactivity, making it a potent candidate for cancer immunotherapy. Studies have shown good tissue cross-reactivity, significant tumor growth inhibition, and acceptable toxicokinetic profile in animal models.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Dingkang Liu, Lichen Bao, Haichao Zhu, Yali Yue, Jing Tian, Xiangdong Gao, Jun Yin
Summary: This study developed a Protease-Activated PSTAGylated BiTE called PAPB, which showed long-acting and highly effective anti-tumor activity in solid tumors. PAPB could release BiTE core to exert its therapeutic effect, and significantly increase T lymphocyte infiltration in tumor tissue. This engineered protein has potential as a promising drug candidate for solid tumor immunotherapy.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Immunology
Kun Du, He Huang
Summary: Accurate structural information is crucial for understanding biological processes and designing drugs. The precision of AlphaFold2 has significantly advanced the prediction of molecular structures, leading to new possibilities in pharmaceutical development. This study demonstrates the potential of AI-assisted drug development and highlights the exceptional binding affinity of a humanized antibody to the PD-L1 protein.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Pierre -Florent Petit, Raphaele Bombart, Pierre -Hubert Desimpel, Stefan Naulaerts, Laurie Thouvenel, Jean-Francois Collet, Benoit J. Eynde, Jingjing Zhu
Summary: The delivery of anti-PD-L1 nanobody through tumor-targeting T cells shows promise in overcoming the limitations of immunotherapy based on PD-L1-specific antibodies.
CANCER IMMUNOLOGY RESEARCH
(2022)
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.
